TaiMed Biologics Inc. (4147) AI Stock Analysis

TaiMed Biologics Inc.

(TPEx:4147)

Select Model

Rating:47Neutral

Price Target:TWD 54.00▼(-12.76% Downside)

Action:initiatedcoverage

Date:11/10/26

Primarily driven by moderate financial performance from a resilient balance sheet and recent positive cash flows, tempered by weak technical signals and unfavorable valuation due to sustained losses.

Positive Factors

Revenue ReboundThe sharp 2025 revenue rebound indicates renewed commercial traction and improved demand for the company’s specialty biologic portfolio. If sustained, stronger sales can provide greater operating leverage, support continued investment in development, and improve the foundation for future profitability.

Negative Factors

Persistent LossesPersistent operating and net losses show that revenue growth has not yet translated into sustainable earnings. Until profitability improves, TaiMed may have less capacity to self-fund expansion, remain exposed to funding needs, and face greater execution pressure in commercializing its portfolio.

TaiMed Biologics Inc. (4147) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 16.54B
Dividend Yield: ―
Average Volume (3M): 920.43K
Price to Earnings (P/E): -103.7
Beta (1Y): 0.31
Revenue Growth: 7.02%
EPS Growth: 25.72%
Country: TW
Employees: 799
Sector: General
Sector Strength: 55
Industry: Biotechnology

TaiMed Biologics Inc. Business Overview & Revenue Model

Company Description

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibod...

TaiMed Biologics Inc. Financial Statement Overview

Summary

Mixed results with a strong equity base and low debt supporting stability, offset by net losses and revenue fluctuations.

Income Statement

32Negative

Balance Sheet

78Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	619.49M	611.35M	610.16M	491.78M	563.01M	413.44M
Gross Profit	283.54M	259.45M	211.22M	225.23M	215.71M	83.95M
EBITDA	-17.44M	-41.66M	-35.57M	-24.61M	-102.74M	-306.83M
Net Income	-138.90M	-167.78M	-201.83M	-194.81M	-279.39M	-478.38M
Balance Sheet
Total Assets	4.50B	4.81B	5.00B	3.89B	4.10B	4.61B
Cash, Cash Equivalents and Short-Term Investments	1.61B	1.77B	1.65B	649.13M	645.40M	960.89M
Total Debt	478.14M	493.12M	522.63M	750.86M	766.14M	567.32M
Total Liabilities	824.49M	953.05M	976.34M	1.33B	1.39B	1.67B
Stockholders Equity	3.68B	3.86B	4.02B	2.57B	2.71B	2.94B
Cash Flow
Free Cash Flow	107.91M	168.47M	-398.90M	-31.75M	-609.97M	-224.84M
Operating Cash Flow	155.12M	191.14M	-379.55M	-25.60M	-605.21M	-211.28M
Investing Cash Flow	288.45M	154.02M	-714.84M	-16.45M	106.11M	190.92M
Financing Cash Flow	-164.53M	-21.64M	1.41B	19.23M	208.38M	2.79M

TaiMed Biologics Inc. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4147 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:4114	61Neutral	TWD 14.97B	17.66	―	3.06%	11.40%	9.36%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4147	47Neutral	TWD 16.47B	-103.67	―	―	7.02%	25.72%
TW:6547	40Underperform	TWD 16.94B	-409.93	―	―	44.37%	78.11%

* General Sector Average

Performance Comparison

TW:4147 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4147	TaiMed Biologics Inc.	61.90	-5.30	-7.89%
TW:4114	Synmosa Biopharma Corp	27.75	-1.98	-6.67%
TW:6547	Medigen Vaccine Biologics Corp.	46.35	9.30	25.10%
TW:6586	CHO Pharma, Inc.	76.20	46.05	152.74%
TW:6589	EirGenix, Inc.	51.70	-22.80	-30.60%
TW:7871	Elixiron Immunotherapeutics (Cayman) Limited	114.50	75.00	189.87%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

TaiMed Biologics Inc. AI Stock Analysis